Abnormalities of lipid metabolism, gallstone disease and gallbladder function

Clinical Lipidology

Volumn 6, Issue 3, 2011, Pages 315-325

  Zanlungo, Silvana ^a   Rigotti, Attilio ^a   Miquel, Juan Francisco ^a   Nervi, Flavio ^a  

^a PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

Author keywords

gallbladder function; gallstone disease; insulin resistance; triglyceride metabolism

Indexed keywords

ABC TRANSPORTER; APOLIPOPROTEIN B; BILE SALT; FATTY ACID; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 15; FIBROBLAST GROWTH FACTOR 19; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LIVER X RECEPTOR; MEMBRANE RECEPTOR; PROTEIN TGR5; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN;

CHOLELITHIASIS; DISEASE ASSOCIATION; DISORDERS OF LIPID AND LIPOPROTEIN METABOLISM; ENERGY METABOLISM; GALLBLADDER DISEASE; GALLBLADDER FUNCTION; GALLBLADDER MOTILITY; GENETIC SUSCEPTIBILITY; HORMONE RELEASE; HUMAN; INSULIN RESISTANCE; LIPID ABSORPTION; METABOLIC REGULATION; METABOLIC SYNDROME X; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

EID: 79959382465     PISSN: 17460875     EISSN: 17584302     Source Type: Journal    
DOI: 10.2217/clp.11.22     Document Type: Review

References (87)

1. Van Erpecum KJ: Pathogenesis of cholesterol and pigment gallstones: an update. Clin. Res. Hepatol. Gastroenterol. 35(4), 281-287 (2011).
2. Stinton LM, Myers RP, Shaffer EA: Epidemiology of gallstones. Gastroenterol. Clin. North Am. 39 (2), 157-169 (2010).
3. Marschall HU, Einarsson C: Gallstone disease. J. Intern. Med. 261(6), 529-542 (2007). (Pubitemid 46835981)
4. Ruhl CE, Everhart JE: Gallstone disease is associated with increased mortality in the United States. Gastroenterology 140(2), 508-516 (2011).
5. Everhart JE, Yeh F, Lee ET et al.: Prevalence of gallbladder disease in American Indian populations: findings from the Strong Heart Study. Hepatology 35(6), 1507-1512 (2002). (Pubitemid 34966906)
6. Miquel JF, Covarrubias C, Villarroel L et al.: Genetic epidemiology of cholesterol cholelithiasis among Chilean Hispanics and Maoris. Gastroenterology 115(4), 937-946 (1998). (Pubitemid 28452942)
7. Cornier MA, Dabelea D, Hernández TL et al.: The metabolic syndrome. Endocr. Rev. 29(7), 777-822 (2008).
8. Haas JT, Biddinger SB: Dissecting the role of insulin resistance in the metabolic syndrome. Curr. Opin. Lipidol. 20(3), 206-210 (2009).
9. Nervi F, Miquel JF, Alvarez M et al.: Gallbladder disease is associated with insulin resistance in a high risk Hispanic population. J. Hepatol. 45(2), 299-305 (2006). (Pubitemid 44026566)
10. Chang Y, Sung E, Ryu S, Park YW, Jang YM, Park M: Insulin resistance is associated with gallstones even in non-obese, non-diabetic Korean men. J. Korean Med. Sci. 23(4), 644-650 (2008).
11. Méndez-Sánchez N, Chavez-Tapia NC, Motola-Kuba D et al.: Metabolic syndrome as a risk factor for gallstone disease. World J. Gastroenterol. 11(11), 1653-1657 (2005). (Pubitemid 40520807)
12. Grundy SM: Metabolic complications of obesity. Endocrine 13(2), 155-165 (2000).
13. Bortnichak EA, Freeman DH Jr, Ostfeld AM et al.: The association between cholesterol cholelithiasis and coronary heart disease in Framingham, Massachusetts. Am. J. Epidemiol. 121(1), 19-30 (1985). (Pubitemid 15150684)
14. Méndez-Sánchez N, Bahena-Aponte J, Chávez-Tapia NC et al.: Strong association between gallstones and cardiovascular disease. Am. J. Gastroenterol. 100(4), 827-830 (2005). (Pubitemid 40592374)
15. Lonardo A, Lombardini S, Scaglioni F et al.: Fatty liver, carotid disease and gallstones: a study of age-related associations. World J. Gastroenterol. 12 (36), 5826-5833 (2006). (Pubitemid 44594251)
16. Méndez-Sánchez N, Zamora-Valdés D, Flores-Rangel JA et al.: Gallstones are associated with carotid atherosclerosis. Liver Int. 28(3), 402-406 (2008). (Pubitemid 351279589)
17. Choi M, Moschetta A, Bookout AL et al.: Identification of a hormonal basis for gallbladder filling. Nat. Med. 12(11), 1253-1255 (2006) (Pubitemid 44706926)
18. Inagaki T, Choi M, Moschetta A et al.: Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab. 2(4), 217-225 (2005)
19. Ganong WF: Gastrointestinal function. In: Review of Medical Physiology. Columbus, McGraw-Hill Professional, OH, USA, 467-479 (2005).
20. Adiels M, Olofsson SO, Taskinen MR, Borén J: Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome. Arterioscler. Thromb. Vasc. Biol. 28(7), 1225-1236 (2008).
21. Lefebvre P, Cariou B, Lien F, Kuipers F, Staels B: Role of bile acids and bile acid receptors in metabolic regulation. Physiol. Rev. 89(1), 147-191 (2009).
22. Trauner M, Claudel T, Fickert P, Moustafa T, Wagner M: Bile acids as regulators of hepatic lipid and glucose metabolism. Dig. Dis. 28(1), 220-224 (2010).
23. Wei J, Qiu de K, Ma X: Bile acids and insulin resistance: implications for treating nonalcoholic fatty liver disease. J. Dig. Dis. 10(2), 85-90 (2009).
24. Hylemon PB, Zhou H, Pandak WM, Ren S, Gil G, Dent P: Bile acids as regulatory molecules. J. Lipid Res. 50(8), 1509-1520 (2009).
25. Houten SM, Watanabe M, Auwerx J: Endocrine functions of bile acids. EMBO J. 25(7), 1419-1425 (2006).
26. Kuipers F, Stroeve JH, Caron S, Staels B: Bile acids, farnesoid X receptor, atherosclerosis and metabolic control. Curr. Opin. Lipidol. 18 (3), 289-297 (2007). (Pubitemid 46743053)
27. Pullinger CR, Eng C, Salen G et al.: Human cholesterol 7a-hydroxylase (CYP7A1) deficiency has a hypercholesterolemic phenotype. J. Clin. Invest. 110(1), 109-117 (2002). (Pubitemid 34743471)
28. Grundy SM, Ahrens EH Jr, Salen G: Interruption of the enterohepatic circulation of bile acids in man: comparative effects of cholestyramine and ileal exclusion on cholesterol metabolism. J. Lab. Clin. Med. 78(1), 94-121 (1971).
29. Beil U, Crouse JR, Einarsson K, Grundy SM: Effects of interruption of the enterohepatic circulation of bile acids on the transport of very low density-lipoprotein triglycerides. Metabolism 31(5), 438-444 (1982). (Pubitemid 12155449)
30. Färkkilä M, Miettinen TA: Lipid metabolism in bile acid malabsorption. Ann. Med. 22(1), 5-13 (1990). (Pubitemid 20110823)
31. Carrella M, Ericsson S, Del Piano C, Angelin B, Einarsson K: Effect of cholestyramine treatment on biliary lipid secretion rates in normolipidaemic men. J. Intern. Med. 229(3), 241-246 (1991).
32. Einarsson K, Ericsson S, Ewerth S et al.: Bile acid sequestrants: mechanisms of action on bile acid and cholesterol metabolism. Eur. J. Clin. Pharmacol. 40(Suppl. 1), S53-S58 (1991).
33. Stone BG, Gavaler JS, Belle SH et al.: Impairment of gallbladder emptying in diabetes mellitus. Gastroenterology 95(1), 170-176 (1988).
34. Nakeeb A, Comuzzie AG, Al Azzawi H, Sonnenberg GE, Kissebah AH, Pitt HA: Insulin resistance causes human gallbladder dysmotility. J. Gastrointest. Surg. 10(7), 940-948 (2006).
35. Smelt AH: Triglycerides and gallstone formation. Clin. Chim. Acta 411 (21-22), 1625-1631 (2010).
36. Portincasa P, Di Ciaula A, Wang HH et al.: Coordinate regulation of gallbladder motor function in the gut-liver axis. Hepatology 47(6), 2112-2126 (2008). (Pubitemid 351945576)
37. Tomlinson E, Fu L, John L et al.: Transgenic mice expressing human fibroblast growth factor-19 display increased metabolic rate and decreased adiposity. Endocrinology 143(5), 1741-1747 (2002). (Pubitemid 34415889)
38. Fu L, John LM, Adams SH et al.: Fibroblast growth factor 19 increases metabolic rate and reverses dietary and leptin-deficient diabetes. Endocrinology 145(6), 2594-2603 (2004). (Pubitemid 38686202)
39. Watanabe M, Houten SM, Mataki C et al.: Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature 439(7075), 484-489 (2006). (Pubitemid 43152840)
40. Thomas C, Gioiello A, Noriega L et al.: TGR5-mediated Bile acid sensing controls glucose homeostasis. Cell Metab. 10(3), 167-177 (2009).
41. Holzbach RT, Marsh M, Olszewski M, Holan K: Cholesterol solubility in bile. Evidence that supersaturated bile is frequent in healthy man. J. Clin. Invest. 52(6), 1467-1479 (1973).
42. Ebert EC, Nagar M, Hagspiel KD: Gastrointestinal and hepatic complications of sickle cell disease. Clin. Gastroenterol. Hepatol. 8(6), 483-489 (2010).
43. Vítek L, Carey MC: Enterohepatic cycling of bilirubin as a cause of 'black' pigment gallstones in adult life. Eur. J. Clin. Invest. 33(9), 799-810 (2003). (Pubitemid 37082867)
44. Thijs C, Knipschild P, Brombacher P: Serum lipids and gallstones: a case-control study. Gastroenterology 99(3), 843-449 (1990)
45. Pihlajamaki J, Gylling H, Miettinen TA, Laakso M: Insulin resistance is associated with increased cholesterol synthesis and decreased cholesterol absorption in normoglycemic men. J. Lipid Res. 45(3), 507-512 (2004). (Pubitemid 38337997)
46. Twisk J, Hoekman MF, Lehmann EM, Meijer P, Mager WH, Princen HM: Insulin suppresses bile acid synthesis in cultured rat hepatocytes by down-regulation of cholesterol 7 a-hydroxylase and sterol 27-hydroxylase gene transcription. Hepatology 21(2), 501-510 (1995).
47. Bennion LJ, Grundy SM: Effects of obesity and caloric intake on biliary lipid metabolism in man. J. Clin. Invest. 56(4), 996-1011 (1975).
48. Biddinger SB, Haas JT, Yu BB et al.: Hepatic insulin resistance directly promotes formation of cholesterol gallstones. Nat. Med. 14(7), 778-782 (2008)
49. Zanlungo S, Miquel JF, Rigotti A, Nervi F: Insulin and cholesterol gallstones: new insights for a complex pathogenic relationship. Hepatology 48(6), 2078-2080 (2008).
50. Biddinger SB, Hernandez-Ono A, Rask-Madsen C et al.: Hepatic insulin resistance is sufficient to produce dyslipidemia and susceptibility to atherosclerosis. Cell Metab. 7(2), 125-134 (2008). (Pubitemid 351168555)
51. Castro J, Amigo L, Miquel JF et al.: Increased activity of hepatic microsomal triglyceride transfer protein and bile acid synthesis in gallstone disease. Hepatology 45(5), 1261-1266 (2007). (Pubitemid 46775789)
52. Loria P, Lonardo A, Lombardini S et al.: Gallstone disease in non-alcoholic fatty liver: prevalence and associated factors. J. Gastroenterol. Hepatol. 20(8), 1176-1184 (2005). (Pubitemid 41602559)
53. Savage DB, Semple RK: Recent insights into fatty liver, metabolic dyslipidaemia and their links to insulin resistance. Curr. Opin. Lipidol. 21(4), 329-336 (2010).
54. Ginsberg HN, Zhang YL, Hernandez-Ono A: Regulation of plasma triglycerides in insulin resistance and diabetes. Arch. Med. Res. 36(3), 232-240 (2005). (Pubitemid 40755136)
55. Hashimoto E, Tokushige K: Prevalence, gender, ethnic variations, and prognosis of NASH. J. Gastroenterol. 46(Suppl. 1), 63-69 (2011).
56. Starley BQ, Calcagno CJ, Harrison SA: Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology 51(5), 1820-1832 (2010).
57. Ioannou GN: Cholelithiasis, cholecystectomy, and liver disease. Am. J. Gastroenterol. 105(6), 1364-1373 (2010).
58. Zhang Y, Liu D, Ma Q, Dang C, Wei W, Chen W: Factors influencing the prevalence of gallstones in liver cirrhosis. J. Gastroenterol. Hepatol. 21(9), 1455-1458 (2006). (Pubitemid 44154716)
59. Acalovschi M, Blendea D, Feier C et al.: Risk factors for symptomatic gallstones in patients with liver cirrhosis: a case-control study. Am. J Gastroenterol. 98(8), 1856-1860 (2003). (Pubitemid 36959170)
60. Wittenburg H: Hereditary liver disease: gallstones. Best Pract. Res. Clin. Gastroenterol. 24(5), 747-756 (2010).
61. Marschall HU, Katsika D, Rudling M, Einarsson C: The genetic background of gallstone formation: an update. Biochem. Biophys. Res. Commun. 396(1), 58-62 (2010).
62. Wang HH, Portincasa P, Afdhal NH, Wang DQ: Lith genes and genetic analysis of cholesterol gallstone formation. Gastroenterol. Clin. North Am. 39(2), 185-207 (2010).
63. Kosters A, Jirsa M, Groen AK: Genetic background of cholesterol gallstone disease. Biochim. Biophys. Acta 1637(1), 1-19 (2003). (Pubitemid 36071591)
64. Katsika D, Grjibovski A, Einarsson C, Lammert F, Lichtenstein P, Marschall HU: Genetic and environmental influences on symptomatic gallstone disease: a Swedish study of 43,141 twin pairs. Hepatology 41(5), 1138-1143 (2005). (Pubitemid 40593922)
65. Puppala S, Dodd GD, Fowler S et al.: A genomewide search finds major susceptibility loci for gallbladder disease on chromosome 1 in Mexican-Americans. Am. J. Hum. Genet. 78(3), 377-392 (2006). (Pubitemid 43291221)
66. Buch S, Schafmayer C, Völzke H et al.: Loci from a genome-wide analysis of bilirubin levels are associated with gallstone risk and composition. Gastroenterology 139(6), 1942-1951 (2010).
67. Lyons MA, Wittenburg H: Cholesterol gallstone susceptibility loci: a mouse map, candidate gene evaluation, and guide to human LITH genes. Gastroenterology 131(6), 1943-1970 (2006). (Pubitemid 44958528)
68. Buch S, Schafmayer C, Völzke H et al.: A genome-wide association scan identifies the hepatic cholesterol transporter ABCG8 as a susceptibility factor for human gallstone disease. Nat. Genet. 39(8), 995-999 (2007). (Pubitemid 47185186)
69. Grünhage F, Acalovschi M, Tirziu S et al.: Increased gallstone risk in humans conferred by common variant of hepatic ATP-binding cassette transporter for cholesterol. Hepatology 46(3), 793-801 (2007). (Pubitemid 47436126)
70. Katsika D, Magnusson P, Krawczyk M et al.: Gallstone disease in Swedish twins: risk is associated with ABCG8 D19H genotype. J. Intern. Med. 268(3), 279-285 (2010).
71. Rudkowska I, Jones PJ: Polymorphisms in ABCG5/G8 transporters linked to hypercholesterolemia and gallstone disease. Nutr. Rev. 66(6), 343-348 (2008). (Pubitemid 351792520)
72. Makishima M, Okamoto AY, Repa JJ et al.: Identification of a nuclear receptor for bile acids. Science 284(5418), 1362-1365 (1999). (Pubitemid 29289663)
73. Parks DJ, Blanchard SG, Bledsoe RK et al.: Bile acids: natural ligands for an orphan nuclear receptor. Science 284(5418), 1365-1368 (1999). (Pubitemid 29289664)
74. Moschetta A, Bookout AL, Mangelsdorf DJ: Prevention of cholesterol gallstone disease by FXR agonists in a mouse model. Nat. Med. 10(12), 1352-1358 (2004). (Pubitemid 40022717)
75. van Berge-Henegouwen GP, Venneman NG, Portincasa P, Kosters A, van Erpecum KJ, Groen AK: Relevance of hereditary defects in lipid transport proteins for the pathogenesis of cholesterol gallstone disease. Scand. J. Gastroenterol. 241(Suppl.), 60-69 (2004). (Pubitemid 40051453)
76. Jiang ZY, Parini P, Eggertsen G et al.: Increased expression of LXR-a, ABCG5, ABCG8, and SR-BI in the liver from normolipidemic, nonobese Chinese gallstone patients. J. Lipid Res. 49(2), 464-472 (2008). (Pubitemid 351213631)
77. Uppal H, Zhai Y, Gangopadhyay A et al.: Activation of liver X receptor sensitizes mice to gallbladder cholesterol crystallization. Hepatology 47(4), 1331-1342 (2008). (Pubitemid 351547919)
78. Wittenburg H: Hereditary liver disease: gallstones. Best Pract. Res. Clin. Gastroenterol. 24(5), 747-756 (2010).
79. Krondl A, Vavrinková H, Michalec C: Effect of cholecystectomy on the role of the gall bladder in fat absorption. Gut 5(6), 607-610 (1964).
80. Amigo L, Husche C, Zanlungo S et al.: Cholecystectomy increases hepatic triglyceride content and very-low-density lipoproteins production in mice. Liver Int. 31(1), 52-64 (2011).
81. Watanabe M, Houten SM, Wang L et al.: Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c. J. Clin. Invest. 113(10), 1408-1418 (2004). (Pubitemid 39071696)
82. Jones S: Mini-review: endocrine actions of fibroblast growth factor 19. Mol. Pharm. 5(1), 42-48 (2008). (Pubitemid 351300033)
83. Thomas C, Auwerx J, Schoonjans K: Bile acids and the membrane bile acid receptor TGR5 -connecting nutrition and metabolism. Thyroid 18(2), 167-174 (2008). (Pubitemid 351271532)
84. Xie MH, Holcomb I, Deuel B et al.: FGF-19, a novel fibroblast growth factor with unique specificity for FGFR4. Cytokine 11 (10), 729-735 (1999). (Pubitemid 29460470)
85. Keitel V, Cupisti K, Ullmer C, Knoefel WT, Kubitz R, Häussinger D: The membrane-bound bile acid receptor TGR5 is localized in the epithelium of human gallbladders. Hepatology 50(3), 861-870 (2009).
86. Juvonen T, Kervinen K, Kairaluoma MI, Kesäniemi YA: Effect of cholecystectomy on plasma lipid and lipoprotein levels. Hepatogastroenterology 42(4), 377-382 (1995).
87. Kuver R: Evaluation of: Amigo L, Husche C, Zanlungo S et al.: Cholecystectomy increases hepatic triglyceride content and very-low-density lipoproteins production in mice. Liver Int. 31(1), 52-64 (2011).